Novaminsulfon (Metamizole Sodium)

Metamizole sodium works by inhibiting cyclooxygenase enzymes, which lowers prostaglandin production and reduces inflammation. In addition, it exerts central analgesic effects by influencing spinal and supraspinal pain pathways, providing both analgesic and antipyretic actions without engaging opioid receptors.

The appropriate dose of Novaminsulfon is determined by the prescribing healthcare professional based on the patient’s age, weight, clinical condition, and response to therapy. Dosage regimens may vary, and patients should follow the specific instructions provided by their prescriber.

Safety data for Metamizole sodium in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful assessment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. The sales team will verify trade or institutional credentials, then respond with pricing, availability, shipping details (including any cold‑chain requirements), and required import documentation.

Novaminsulfon offers analgesic and antipyretic effects similar to NSAIDs but with a distinct mechanism that does not involve COX‑1 inhibition, potentially reducing gastrointestinal side effects. Unlike opioids, it does not act on opioid receptors, so it carries a lower risk of dependence and respiratory depression, though it has its own safety considerations such as rare blood dyscrasias.

Novaminsulfon should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to direct sunlight to maintain stability and potency throughout its shelf life.

Novaminsulfon is administered orally, typically in tablet or liquid form, as directed by a healthcare professional. The medication should be taken with or without food according to the prescriber’s instructions, and the full prescribed course should be completed unless advised otherwise.

The most serious adverse reactions to Novaminsulfon include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of infection, fever, or hypersensitivity, and immediate medical attention is required if these occur.

Novaminsulfon is contraindicated in individuals with a known hypersensitivity to metamizole or any pyrazolone derivatives, those with a history of agranulocytosis, and patients with severe liver or kidney impairment unless specifically advised by a physician. It should also be avoided in patients taking other myelosuppressive agents without close monitoring.